{"nctId":"NCT02576847","briefTitle":"Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel","startDateStruct":{"date":"2015-10","type":"ACTUAL"},"conditions":["Rosacea"],"count":307,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Omiganan"]}],"interventions":[{"name":"Omiganan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy, male and nonpregnant female subjects, 18 years of age or older.\n2. A diagnosis of severe papulopustular rosacea using the Investigator Global Assessment grading scale at baseline\n3. Subjects with the presence of telangiectasia at Baseline\n4. Subjects with the presence of facial erythema associated with their rosacea at Baseline\n\nExclusion Criteria:\n\n1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).\n2. Subjects with nodular rosacea\n3. Standard exclusion criteria.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With 1 or More Treatment-related Treatment-Emergent Adverse Events","description":"Number of subjects with 1 or more treatment-related Treatment-Emergent Adverse Events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":307},"commonTop":["Rosacea","Headache","Viral upper respiratory tract infection","Application site pain","Upper respiratory tract infection"]}}}